(ANIX) Anixa Biosciences - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03528H1095

Stock: CAR-T Therapy, Cancer Vaccines, Ovarian Cancer, Breast Cancer, Retired Protein

Total Rating 23

Risk 67

Buy Signal -0.45

Biotechnology » Biotechnology
Age: 39.1y

Market Cap: 101m
Avg Trading Vol: 689K USD

ATR: 7.11%
Peers RS (IBD): 9.50

EPS (Earnings per Share)

EPS CAGR: 103.40%
EPS Trend: 53.8%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 0.00%
Rev. Trend: -25.7%

Last SUE: 0.00
Qual. Beats: 0

Risk 5d forecast
Volatility	82.6%
Relative Tail Risk	-16.9%

Reward TTM
Sharpe Ratio	0.23
Alpha	-19.80

Character TTM
Beta	1.245
Beta Downside	1.139

Drawdowns 3y
Max DD	64.32%
CAGR/Max DD	-0.14

Description: ANIX Anixa Biosciences January 19, 2026

Anixa Biosciences (NASDAQ: ANIX) is a U.S. biotech focused on oncology-focused cell-therapy and vaccine platforms. Its lead program, liraltagene autoleucel, is a chimeric endocrine-receptor (CER) T-cell therapy targeting ovarian cancer, while parallel efforts aim to create a breast-cancer vaccine and a broader vaccine discovery pipeline for high-incidence malignancies such as lung, colorectal, and prostate cancer.

Key external metrics that shape Anixa’s outlook include: (1) the global oncology CAR-T market, projected to exceed $15 billion by 2028, providing a sizable addressable pool; (2) the company’s latest 10-Q (Q3 2024) reported cash runway of roughly $45 million, enough for at least 12 months of R&D spending at current burn rates; and (3) recent Phase 1/2 data for liraltagene autoleucel showed a disease-control rate of 68 % in a small ovarian-cancer cohort, a figure that, if confirmed, would place the asset above the median efficacy of comparable early-stage CAR-T candidates.

For a deeper quantitative view, you may find ValueRay’s analyst platform useful.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.45 > 0.02 and ΔFCF/TA -5.14 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.45 > 3% & CFO -7.17m > Net Income -10.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.08 > 1.5 & < 3
Outstanding Shares: last quarter (32.5m) vs 12m ago 1.74% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -17.39 > 6 (EBITDA TTM -11.7m / Interest Expense TTM -673.0k)

Altman Z'' -15.00

A: 0.87 (Total Current Assets 15.9m - Total Current Liabilities 1.97m) / Total Assets 16.1m
B: -15.65 (Retained Earnings -251.7m / Total Assets 16.1m)
C: -0.62 (EBIT TTM -11.7m / Avg Total Assets 18.8m)
D: -118.0 (Book Value of Equity -251.3m / Total Liabilities 2.13m)
Altman-Z'' Score: -173.4 = D

What is the price of ANIX shares?

As of February 08, 2026, the stock is trading at USD 2.96 with a total of 132,395 shares traded.
Over the past week, the price has changed by -2.63%, over one month by -6.92%, over three months by -27.09% and over the past year by -7.21%.

Is ANIX a buy, sell or hold?

Anixa Biosciences has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIX.

StrongBuy: 1
Buy: 2
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ANIX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	10	237.8%
Analysts Target Price	10	237.8%
ValueRay Target Price	2.8	-4.1%

ANIX Fundamental Data Overview February 02, 2026

P/S = 481.5351
P/B = 6.6931
Revenue TTM = 0.0 USD
EBIT TTM = -11.7m USD
EBITDA TTM = -11.7m USD
Long Term Debt = 204.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 41.0k USD (from shortTermDebt, last quarter)
Debt = 204.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.04m USD (from netDebt column, last quarter)
Enterprise Value = 86.5m USD (101.5m + Debt 204.0k - CCE 15.2m)
Interest Coverage Ratio = -17.39 (Ebit TTM -11.7m / Interest Expense TTM -673.0k)
EV/FCF = -12.06x (Enterprise Value 86.5m / FCF TTM -7.17m)
FCF Yield = -8.29% (FCF TTM -7.17m / Enterprise Value 86.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 27.0k) / Revenue TTM)
Tobins Q-Ratio = 5.38 (Enterprise Value 86.5m / Total Assets 16.1m)
Interest Expense / Debt = 25.0% (Interest Expense 51.0k / Debt 204.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -9.24m (EBIT -11.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.08 (Total Current Assets 15.9m / Total Current Liabilities 1.97m)
Debt / Equity = 0.01 (Debt 204.0k / totalStockholderEquity, last quarter 15.2m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -1.04m / EBITDA -11.7m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -1.04m / FCF TTM -7.17m)
Total Stockholder Equity = 16.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.01% (Net Income -10.9m / Total Assets 16.1m)
RoE = -66.55% (Net Income TTM -10.9m / Total Stockholder Equity 16.4m)
RoCE = -70.39% (EBIT -11.7m / Capital Employed (Equity 16.4m + L.T.Debt 204.0k))
RoIC = -56.30% (negative operating profit) (NOPAT -9.24m / Invested Capital 16.4m)
WACC = 10.52% (E(101.5m)/V(101.7m) * Re(10.50%) + D(204.0k)/V(101.7m) * Rd(25.0%) * (1-Tc(0.21)))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.18%
Fair Price DCF = unknown (Cash Flow -7.17m)
EPS Correlation: 53.85 | EPS CAGR: 103.4% | SUE: 4.0 | # QB: 1
Revenue Correlation: -25.66 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-04-30): EPS=-0.08 | Chg30d=+0.020 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-10-31): EPS=-0.34 | Chg30d=+0.040 | Revisions Net=+0 | Growth EPS=+0.0% | Growth Revenue=+0.0%
EPS next Year (2027-10-31): EPS=-0.37 | Chg30d=-0.010 | Revisions Net=+0 | Growth EPS=-8.8% | Growth Revenue=+0.0%

Additional Sources for ANIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle